Evaluation of gastric polyps in patients with upper gastrointestinal endoscopy

Lie Zheng

Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine

Xinli Wen (✉ 492688049@qq.com)

Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine

Yan-Cheng Dai

Institute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine

Xiao-Xiao QianTu

Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine

Hai-Feng He

Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine

Ya-Li Zhang

Department of Gastroenterology, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine

Research article

Keywords: Endoscopic polypectomy, hyperplastic polyp, gastric polyp

Posted Date: December 13th, 2019

DOI: <https://doi.org/10.21203/rs.2.18874/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

BACKGROUND

According to the study population, incidence of gastric polyps (GP) varies from 0.33% to 6.7% in various studies. Most GPs consist of proliferative polyps (HP), gastric fundus polyps (FGP) and adenomatous polyps (APs). Despite the high malignant AP potential, sporadic FGP has no malignant potential. On the contrary, HP has a lower risk of potential harm. It is not sufficient to perform biopsies to determine the presence of polyp types and displacements, therefore, some polyps may require extensive biopsy or complete resection.

METHODS

This retrospective study included GP patients or polyphenic lesions with polyps or malignant histology found in polyps or gastroscopy at the Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine from 2017 to 2019.

RESULTS

In a series of 10,000 upper gastrointestinal endoscopy, 384 patients (0.38%) were found to have GPs. Of these patients, 98 (25.5) were male and 286 (74.5) were female. The average age of the patients was 62.8 ± 10.4 (36-75) years. HP, AP and FGP frequencies were 88.5%, 5.2% and 2.1%, respectively. The polyp size of 274 (71.3%) patients was ≤ 1 cm. Polyp was identified in 262 (68.2%) patients. The most common polyps are the antrum and the corpus. Endoscopic respiratory polypectomy was performed on 128 patients. Bleeding events have been observed and endoscopic treatment is required after ESP.

CONCLUSION

In current study, GP frequency was low (0.38%), and HP frequency may be high due to high frequency of *Helicobacter pylori* (HPy) infection in China. Due to the high frequency of HPy infection and the short-term use of proton pump use, FGP frequency may be low.

Background

Polyps are usually asymptomatic and > 88% are detected by esophagogastroduodenoscopy for other reasons. Large polyps can cause bleeding, anemia, abdominal pain, or obstruction due to their position [1]. The diagnosis of polyps must be confirmed by histological examination [2]. The frequency of gastric polyps (GPs) and other polyps varies depending on the population under study [3]. The prevalence of polyps is 0.6–6% [4]. Most polyps detected in the stomach are hyperplastic polyps (HPs), fundic gland polyps (FGPs) and adenomatous polyps (APs) [5]. HPs are most common in people with *Helicobacter pylori* infection [6]. In countries with low rates of *H. pylori* infection, FGPs are more common. The long-term use of proton pump inhibitors (PPIs) increases the frequency of FGPs [7]. The importance of GPs

arises from the fact that some GPs have malignant potential or are associated with some hereditary syndromes. Although GPs appear in a number of congenital diseases, such as familial adenomatous polyposis, adolescent polyposis and Peutz–Jeghers syndrome, they are most commonly misdiagnosed [8]. There is an increased risk of cancer in polyps other than FGPs and inflammatory fibrinoid polyp (IFPs). In addition to FGP and polyps such as inflammatory fibrinoid polyp (IFP), the risk of cancer is increased with polyps. Although the risk of malignant transformation in HPs is low, it is more common in APs. Due to their malignant potential and symptomatic nature, GPs are removed completely with endoscopic resection or surgery [9].

In this study, our aim was to evaluate demographic, clinical, endoscopic, and histological data of patients with polyps or polypoid lesions. In addition, we evaluated diagnostic procedures, treatments and their complications, and the relationship between age and size and number of polyps.

Methods

At the Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine, we retrospectively reviewed the results of 10000 consecutive esophagogastroduodenoscopy (EGD) procedures performed for various reasons between September 2017 and July 2019. Patients with GP or polyphenic lesions with polyps or malignant histology found by EGD were included in this study. We excluded patients who did not have polyps detected by biopsy, and those who had previously participated in the study but for whom we could not obtain pathological records. We evaluated age and sex; endoscopic indications and findings; GP count, size and location; histological diagnostic methods; and endoscopic treatment complications. The relationship between age and size and number of polyps was also assessed. The endoscope used was the Olympus EG 290 WR videoendoscope. The size of the polyps was estimated by comparing it with the opening size of the biopsy forceps. In patients with multiple polyps, polyp diameter was calculated by measuring the largest polyp diameter.

Statistical Analysis

Data were analyzed using the SPSS software package program for Windows 23.0 (SPSS, Chicago, IL, USA). Descriptive statistics are used to describe continuous variables. The χ^2 (Fisher's exact) test was used to classify variables and expressed as the number of observations (and percentages). Statistical significance was obtained when the p value was <0.05 . The Kolmogorov-Smirnov test was used to analyze the category data corresponding to the normal distribution, and Spearman correlation was used if the distribution of variables was abnormal.

Results

We included 1000 patients receiving EGD in our endoscopy unit. GPs were found in 384 patients, giving an incidence of 0.38%.

Table 1. Demographic data and clinical characteristics of patients

	Patients, <i>n</i> (%)		Patients, <i>n</i> (%)
Sex			
Male	98 (25.5)	Polyp size (mean $\pm$ SD) (mm)	10.6 $\pm$ 4.1 (3–21)
Female	286 (74.5)	Distribution of polyp size (mm)	
Age (yr)		< 6	98 (25.5)
Male	63.8 $\pm$ 10.0 (39–75)	6–10	176 (45.8)
Female	61.2 $\pm$ 9.8 (36–74)	11–18	90 (23.4)
Symptoms			
Dyspepsia	126 (32.8)		
Anemia	82 (21.3)		
Abdominal pain	70 (18.2)		
Other	106 (27.6)		

Patient characteristics are shown in Table 1. Among these patients, 34 (8.9%) were aged 41 years, 72 (18.7%) 41–50 years, 84 (21.9%) 51–60 years, 34 (33.8%) 61–70 years, and 64 (16.7%) > 70 years.

The average polyp diameter was 10.6 $\pm$ 4.1 (range: 3–21) mm: 98 (25.5%) were $\leq$ 5 mm, 176 (45.8%) 6–10 mm, 90 (23.4%) 11–20 mm, and 20 (5.2%) > 20 mm. There were no significant correlations between age and polyp size ($P > 0.05$).

Endoscopy revealed that 262 (68.2%) patients had one polyp, and 122 (31.8%) more than one. Age was not significantly associated with polyp count ($P > 0.05$). Two hundred and four (53.1%) patients underwent histopathological diagnosis of polyposis, 150 (39.1%) underwent polypectomy with forceps biopsy, and 30 (7.8%) underwent polypectomy and surgical resection. One patient could not be diagnosed by endoscopic biopsy. Histologically, the denudeated polyp was defined as IFP. Twenty (5.2%) patients had foveolar hyperplasia. Table 2 summarizes the histological distribution of polyps. Only one (0.3%) patient with GPs was diagnosed with adenocarcinoma. The most common localization of GPs was the antrum (150/384; 39.1%), followed by the corpus (112/384, 29.2%) and cardia (70/384, 18.2%). Polypectomy was performed in 150 (39.1%) patients using forceps biopsy. None of the 74 patients who underwent polypectomy using forceps biopsy had complications, and only one patient had bleeding in the form of a leak during polypectomy and bleeding was controlled by sclerotherapy.

Table 2. Distribution of histopathological types of GPs

	(<i>n</i> = 384)	%
Hyperplastic polyp	340	88.5
Foveolar hyperplasia	20	5.2
Fundic gland polyp	8	2.1
Adenomatous polyp	8	2.1
Adenomatous and hyperplastic polyp	2	0.5
Inflammatory fibroid polyp	2	0.5
Fibrotic polyp	2	0.5
Adenocarcinoma	1	0.3
Carcinoid tumor	1	0.3

Polypectomy with snare was performed in 128 (33.3%) patients, and was performed alone or in combination with sclerotherapy, endoclip, or endoloop treatments. The distribution of different polypectomy methods with snare is given in Table 3. In patients undergoing sectional polypectomy, polyp diameter was 10.6 ± 4.1 (3–21) mm. In 118 (92%) patients no complications related to polypectomy were observed. Bleeding was observed in eight patients during unknown polypectomy. Spontaneous bleeding occurred in two patients during endoscopic polypectomy and sclerotherapy was used in two patients. Bleeding was observed at the base of the polyp, and hematemesis occurred 4 h after polypectomy. Bleeding was controlled by sclerotherapy and blood transfusions were not required.

Table 3. Distribution of types of snare polypectomy

	Patients	%
PS	75	58.6
PS + sclerotherapy	41	32.0
PS + endoloop	7	5.5
PS + sclerotherapy + endoloop	3	2.3
PS + sclerotherapy + endoclip	2	1.6
Total	128	100

PS: Polypectomy with snare

Discussion

We found that the most common symptoms of GPs were nausea, anemia and abdominal pain. We also found that GPs were mostly located in the abdominal anterior, and the most common type of histopathology was HP. GP incidence was 6.35% in 2645 EGD procedures^[10]. The most common type of polyp was GFP, which accounted for 77% of all polyps, while HP and Foveolar hyperplasia [FHP] accounted for 17% of all polyps^[11]. Sixteen percent of lesions defined as polyps did not have histopathological evidence of polyps or malignant histology. A previous study associated the high frequency of GFPs with long-term PPI use and low frequency of *H. pylori* infection^[12]. In a previous study of 3024 endoscopic procedures, the most common type of polyp was HP^[13,14]. The authors concluded that this may have been due to an increase in *H. pylori* infection^[15]. GPs (1.4%) were reported in 36 patients, the most common type being HP, in 2657 EGD procedures^[16]. In another study of 900 EGD procedures, GPs were found in 126 (1.4%) patients. Histological examination revealed 48 patients with HPs, 17 with GFPs, six with APs, and 118 had gastritis or normal histology^[17].

The most common type of polyp in our study was HP. The rate of *H. pylori* infection in China is 60–70%^[18]. In countries with high frequency of *H. pylori*, the most common type of polyp is HP^[19]. In a study of 3153 EGD procedures, 135 (4.3%) patients had polypoid lesions^[20,21]. The average age of the patients was 65 years. Polyp types were HP (52.3%), FGP (7.6%) and AP (3.5%). In addition, the incidence of adenocarcinoma was 1.8%. Histopathological examination of common mucosa showed that 29.7% of patients had polyps by EGD. A total of 153 patients (0.59%) were reported in 26 000 endoscopic procedures^[22,23]. Among these patients, 41.2% were female and the average age was 64 years. The frequency of the different types of polyps was 72.4% HP, 17.2% FGP was 17.2%, and 11.8% AP. Adenocarcinoma was found in patients with HP or AP. In a study by Molaei *et al*, HP frequency was 69.2%, FGP was 6.6%, and AP was 4.7%. The average age of the patients was 49 years and 73% were male. In 87% of cases, polyp size was < 10 mm^[24]. In a study by Fann *et al*, the mean age of patients was 54.7 years, 63% were female, and 37% were male^[25]. In our study, ~80% of patients diagnosed with GPs were > 50 years old. There was no relationship between age and size and number of polyps. HPs and APs are commonly present in elderly people^[26]. In our study, the incidence of GPs was 0.38%, which was lower than in most other studies. This may be due to patients who have been excluded because they had benign lesions or inappropriate polyp sampling. There have been few studies on GPs in China. In a study conducted by Gencosmanoglu *et al*, the incidence of GPs was 3.6%, and 48% of the polyps were HPs, 19% FHPs, and 17% FGP^[27]. The average age of the patients was 52 years and the proportion of women was 56.4%. In 57.2% of patients, polyp size was < 5 mm^[28]. In a study by Karaman *et al*, 69 (0.59%) patients had a GP in 11 598 EGD procedures. Although 69% of polyps are HP, 10% are FGPs^[29]. Buyukasik *et al* found that 66.7% of polyps were HPs in 55 887 EGD procedures^[30]. Vatansever *et al* found that the incidence of GPs was 2.22%, and the highest frequency of HPs was 36.2%^[31]. In our study, the most common type of polyp was HP. However, HP frequency was higher than in other studies. In addition, FGP frequency was significantly lower than in other studies. However, in a study conducted by

Demiryilmaz *et al*, GPs were found in 66 (1.95%) patients in 3375 EGD procedures^[32]. A total of 88 polypoid wound lesions were detected in these patients. Histopathological examination of polyps showed that HPs accounted for 80.7%, inflammatory polyps 17%, and APs 2.3%^[33]. FGP was not detected. In some studies, FGP was the most common type of polyp.

The frequency of polyps increases due to the frequency of *H. pylori* infection and increased use of PPIs. Many studies have shown an increase in the frequency of FGPs in patients using PPIs^[34]. This relationship can cause anxiety among doctors and patients who need to use PPIs for a long time. In a study by Jalving *et al*, there was no increase in FGP frequency in patients using PPIs for < 1 year^[35]. However, it has been found that long-term use of PPIs increases the risk of developing FGP fourfold. However, the risk of displacement did not increase. When subgroup analysis was performed, a significant increase in the risk of developing FGPs was observed in patients who had used PPIs for > 5 years. Patients with omeprazole and patients with other PPIs are at increased risk for developing FGPs due to long-term use of PPIs^[7]. However, no increase in FGP frequency in patients using PPIs has been observed in some other studies^[36]. A total of 30 347 *H. pylori*-negative patients were evaluated and FGP frequency was similar to that in 28 096 patients without PPIs and 2251 using PPIs, and PPI users had no increased risk of polyps^[37]. This may be due to short-term use of PPIs. In a study by Choudhry *et al*, patients with PPIs had the highest risk of developing FGPs after an average of 37 mo^[38]. Hongo *et al* prospectively studied the development of FGPs and HPs in patients with long-term PPI use, which was associated with an increase in GFP frequency in *H. pylori*-negative patients. The formation of FGPs was not related to hypergastrinemia.

However, HP development is associated with *H. pylori* infection and hypergastrinemia^[39]. In our study, FGPs were found in eight patients. It is known that *H. pylori* infection reduces FGP formation, and these polyps are common in *H. pylori*-negative patients. This low incidence may be related to high rates of *H. pylori* infection in China. However, even in countries with high *H. pylori* infection rates, FGP frequency may be high, but these polyp have not been observed in several studies^[40]. Frequency of FGPs is related to long-term PPI use. No increased risk of short-term use has been observed. The most common reason for EGD surgery is complaints of indigestion. The frequency of FGPs in our patients was low; probably because they had been treated with PPIs for a short time. Also, because these polyps are so small, they may be missed during EGD surgery or may be neglected due to their indistinct endoscopic appearance.

In our study, 20 (5.2%) patients had FHPs. These lesions are considered to be precursors of HPs, although it is unclear how long FHPs take to change to HPs. The lesions may be stable or may grow or shrink. However, whether they are HP precursors is still controversial. It has been shown that the basic structure and cytological criteria of FHPs and HPs can be easily distinguished by biopsy material obtained by endoscopic forceps. These lesions are not the result of HP precursors^[41]. FHPs are common lesions in research. In our study, APs were detected in eight patients. APs have been shown to account for 2.1% of GPs. These polyps are more common in patients with stomach cancer and have high malignant potential of 6.8–55.3%^[42]. Lesion size, height of atypical hyperplasia and presence of intestinal

epithelium are risk factors for malignant tumor development. Even adenomas with low displacement during long-term follow-up have malignant potential. Therefore, it is recommended to remove these lesions ^[26]. In addition, IFP was detected in one patient in our study. These polyps are not always diagnosed as endoscopic biopsies because they are local ^[33]. Because our case was not diagnosed by endoscopic biopsy, it was diagnosed after surgical removal ^[34].

A total of 128 patients (33.3%) underwent snare polypectomy in our study. One patient required endoscopic control of bleeding. Low rates of hemorrhage caused by endoscopic polypectomy can be treated by sclerotherapy, endoclip or endoloop procedures. No death or penetration occurred in any patient. Snare polypectomy is a safe and effective way to diagnose and treat polyps.

In conclusion, the GP frequency in our study was low (0.38%). HP polyps were the most common types of gastric polyps. Of note, as GPs may have a risk of developing adenocarcinoma or precancerous lesions, we suggest that appropriate GP resection technology (such as biopsy forceps or mesenchymal resection) should be applied.

Abbreviations

GPs:gastric polyps; HP:hyperplastic polyps ; FGP:gastric polyps; APS:adenomatous polyps ;PPI:proton pump inhibitor;IFP:inflammatory fibrin;

Declarations

Ethics approval and consent to participate

This study was performed in compliance with the Declaration of Helsinki. The investigation location and source of the participants in this investigation was Shaanxi Hospital of Traditional Chinese Medicine., where institutional Review Board and Ethics Committee approved the study, granted ethical approval, and all patients provided written informed consent to participate in this prospective study.

Consent for publication

Written informed consent was obtained from the patients and any accompanying images. Patients gave consent for their personal or clinical details along with any identifying images to be published in this study. all authors have read and approved the manuscript.

All authors read and approved the final draft.

*** Availability of data and material** No additional data are available

*** Competing interests** The authors declare that there are no conflicts of interest related to this study.

***Funding Supported by** Shaanxi province natural science basic research program-general project[NO: 2019JM-580],Shaanxi provincial hospital of traditional Chinese medicine[NO.2018-04],Project of shaanxi administration of traditional Chinese medicine[NO.2019-ZZ-JC010],National Natural Science Foundation of China [No.81573892.No.81704009.No.81873253] and Research Project of Shanghai Health and Family Planning Commission [No.201640122].

*** Authors' contributions:** Z L and YCD contributed equally to this work, who performed the majority of experiments ̳HFHe, YLZanalyzed the data; Z L and XLW designed and coordinated the research; Z L wrote and revised the paper.

*** Acknowledgements**We would like to thank our colleagues in the Institute of Digestive Disease for their help and support in this research.

References

1. Assarzadegan N, Montgomery E. Gastric polyps[J]. Diagnostic Histopathology, 2017, 23(12):521-529.
2. Brosens L A, Wood L D, Offerhaus G J, et al. Pathology and Genetics of Syndromic Gastric Polyps[J]. International Journal of Surgical Pathology, 2016, 24(3):185.
3. Argüello V L, Córdova H, Uchima H, et al. Gastric polyps: Retrospective analysis of 41,253 upper endoscopies.[J]. Gastroenterología Y Hepatología, 2017, 40(8).
4. Nam S Y, Park B J, Ryu K H, et al. Effect of Helicobacter pylori infection and its eradication on the fate of gastric polyps[J]. European Journal of Gastroenterology & Hepatology, 2016, 28(4):1.
5. Nam S Y, Park B J, Ryu K H, et al. Effect of Helicobacter pylori eradication on the regression of gastric polyps in National Cancer Screening Program.[J]. Korean Journal of Internal Medicine, 2017, 33(3).
6. Nakamura K, Nonaka S, Nakajima T, et al. Clinical outcomes of gastric polyps and neoplasms in patients with familial adenomatous polyposis[J]. Endoscopy International Open, 2017, 5(3):E137-E145.
7. McDuffie L A, Sabesan A, Allgäuer M, et al. β -Catenin activation in fundic gland polyps, gastric cancer and colonic polyps in families afflicted by 'gastric adenocarcinoma and proximal polyposis of the stomach' (GAPPS)[J]. Journal of Clinical Pathology, 2016, 69(9):826.
8. Corral J E, Keihanian T, Diaz L I, et al. Management patterns of gastric polyps in the United States[J]. Frontline Gastroenterology, 2018:flgastro-2017-100941-.
9. Takeuchi C, Yamamichi N, Shimamoto T, et al. Gastric polyps diagnosed by double-contrast upper gastrointestinal barium X-ray radiography mostly arise from the Helicobacter pylori-negative stomach with low risk of gastric cancer in Japan[J]. Gastric Cancer, 2017, 20(2):314-321.
10. Markowski A R, Markowska A, Guzinska-Ustymowicz K. Pathophysiological and clinical aspects of gastric hyperplastic polyps[J]. World Journal of Gastroenterology, 2016, 22(40):8883-.
11. Zhang H, Zhu J, Cui R, et al. Su1233 - Gastric Hyperplastic Polyps in Patients with Autoimmune Metaplastic Atrophic Gastritis at a Large Tertiary Medical Center[J]. Gastroenterology, 2018, 154(6):S-

12. Gonzalez R S, Adsay V, Graham R P, et al. Massive gastric juvenile-type polyposis: a clinicopathological analysis of 22 cases[J]. *Histopathology*, 2016, 70(6):918-928.
13. Kazumi, Tetsuya, Hirotooshi, et al. Two cases of adenocarcinoma occurring in sporadic fundic gland polyps observed by magnifying endoscopy with narrow band imaging[J]. *World Journal of Gastroenterology*, 2016, 22(40):9028-9034.
14. Abe T, Kato M, Kohno S, et al. Foveolar gastric metaplasia presenting as a duodenal tumor with an atypical appearance: a case report[J]. *Journal of Medical Case Reports*, 2016, 10(1):355.
15. Cheesman A R, Greenwald D A, Shah S C. Current Management of Benign Epithelial Gastric Polyps. [J]. *Current Treatment Options in Gastroenterology*, 2017(10):1-15.
16. Diaconescu S, Miron I, Gimiga N, et al. Unusual Endoscopic Findings in Children: Esophageal and Gastric Polyps: Three Cases Report[J]. *Medicine*, 2016, 95(3):e2539.
17. Vyas M, Yang X, Zhang X. Gastric Hamartomatous Polyps—Review and Update[J]. *Clinical Medicine Insights Gastroenterology*, 2016, 9(9):3-10.
18. Jeong C Y, Kim N, Lee H S, et al. Risk Factors of Multiple Gastric Polyps according to the Histologic Classification: Prospective Observational Cohort Study[J]. 2019, 74(1):17.
19. Olmez S, Sayar S, Saritas B, et al. Evaluation of patients with gastric polyps.[J]. *North Clin Istanb*, 2018:41-46.
20. Kassem N, Ismail O M, Elomri H, et al. Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature:[J]. *American Journal of Case Reports*, 2017, 18:794-798.
21. Chan K, Brown I S, Kyle T, et al. Chief cell predominant gastric polyps: a series of 12 cases with literature review.[J]. *Histopathology*, 2016, 68(6):825-833.
22. Castro R, Pimentelnunes P, Dinisribeiro M. Evaluation and management of gastric epithelial polyps. [J]. *Best Practice & Research Clinical Gastroenterology*, 2017, 31(4):381.
23. Brosens L A A, Giardiello F M, Offerhaus G J, et al. Syndromic Gastric Polyps: At the Crossroads of Genetic and Environmental Cancer Predisposition[J]. *Advances in Experimental Medicine & Biology*, 2016, 908:347.
24. Lami G, Galli A, Macrì G, et al. Gastric and duodenal polyps in familial adenomatous polyposis patients: Conventional endoscopy vs virtual chromoendoscopy (fujinon intelligent color enhancement) in dysplasia evaluation.[J]. *World Journal of Clinical Oncology*, 2017, 8(2):168-177.
25. Fan N N . Changes in the spectrum of gastric polyps in the Chinese population[J]. *World Journal of Gastroenterology*, 2015, 21(33):9758..
26. Horvath B, Pai R K. Prevalence of *Helicobacter pylori* in Gastric Hyperplastic Polyps[J]. *International Journal of Surgical Pathology*, 2016, 24(8):704.
27. Gencosmanoglu R , Sen-Oran E , Kurtkaya-Yapicier O , et al. Gastric polypoid lesions:Analysis of 150 endoscopic polypectomy specimens from 91 patients[J]. *World Journal of Gastroenterology*, 2003, 9(10):2236-2239..

28. Karpińska-Kaczmarczyk K, Lewandowska M, Białek A, et al. Gastric hyperplastic polyps coexisting with early gastric cancers, adenoma and neuroendocrine cell hyperplasia[J]. Polish Journal of Pathology Official Journal of the Polish Society of Pathologists, 2016, 67(1):33.
29. Karaman A, Deniz K, Karaman H, Gürsoy Ş, Başkol M, Güven K, et al. Prevalence and histopathological condition of gastric polyps in Central Anatolia. Endoskopi Dergisi 2011;2:56–8.
30. Buyukasik K, Sevinc MM, Gunduz UR, Ari A, Gurbulak B, Toros AB, et al. Upper gastrointestinal tract polyps: what do we know about them? Asian Pac J Cancer Prev 2015;16:2999–3001
31. Vatansever S, Akpınar Z, Alper E, İpek S, Yazıcıoğlu N, Ekin N, et al. Gastric polyps and polypoid lesions: Retrospective analysis of 36650 endoscopic procedures in 29940 patients. Turk J Gastroenterol 2015;26:117–22.
32. Demiryilmaz I, Albayrak Y, Yilmaz SP. Frequency of various types of gastric polyp. Cumhuriyet Med J 2011;33:209–14
33. Koh J S, Joo M K. Helicobacter pylori eradication in the treatment of gastric hyperplastic polyps: beyond National Health Insurance[J]. Korean J Intern Med, 2018, 33(3):490-492.
34. Miyamoto S, Kato M, Matsuda K, et al. Gastric Hyperplastic Polyps Associated with Proton Pump Inhibitor Use in a Case without a History of Helicobacter pylori Infection:[J]. Internal Medicine, 2017, 56(14):1825-1829.
35. Tran-Duy A, Spaetgens B, Hoes A W, et al. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis[J]. Clinical Gastroenterology & Hepatology the Official Clinical Practice Journal of the American Gastroenterological Association, 2016, 14(12):1706-1719.e5.
36. Khalaf M, Brock A S, Castell D. Sporadic Fundic Gland Polyps and Gastric Acid Suppression Level[J]. American Journal of the Medical Sciences, 2017, 354(6):561.
37. Mori H, Nishiyama N, Kobara H, et al. The use of a detachable multiple polyp catcher to facilitate accurate location and pathological diagnosis of resected polyps in the proximal colon[J]. Gastrointestinal Endoscopy, 2016, 83(1):262-263.
38. Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998;110:615–21.
39. Anjiki H, Mukaisho K I, Yu K, et al. Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy[J]. Clinical Journal of Gastroenterology, 2017, 10(2):1-9.
40. Shiotani A, Katsumata R, Gouda K, et al. Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors[J]. Digestion, 2018, 97(2):154-162.
41. Pipek L Z, Jardim Y J, Gustavo Heluani Antunes de Mesquita, et al. Large primary hepatic gastrinoma in young patient treated with trisegmentectomy: A case report and review of the literature[J]. World Journal of Hepatology, 2018, 10(7):517-522.

42. Waldum H L, Sagatun L, Mjønes P. Gastrin and Gastric Cancer:[J]. *Frontiers in Endocrinology*, 2017, 8(3):801-811.